SCHEMBL4959700

SCHEMBL4959700

OCc1[nH]cnc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
CYP3A4 P08684 1/20 0.55
MAPT P10636 1/20 0.55
IDO1 P14902 4/20 0.42
ADORA3 P0DMS8 4/20 0.41
ADORA2A P29274 4/20 0.41
ADORA1 P30542 4/20 0.41
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
FLT1 P17948 1/20 0.40
KDR P35968 1/20 0.40
TEK Q02763 1/20 0.40
ALOX15 P16050 1/20 0.39
DPP4 P27487 1/20 0.38
AR P10275 1/20 0.37
NOTUM Q6P988 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27707292 0.81 KDM4E (0.55) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL1566538 0.81 KDM4E (0.55) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL27554380 0.81 KDM4E (0.55) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL1949484 0.79 KDM4E (0.53) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL1952140 0.78 CYP3A4 (0.52) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL14409315 0.75 KDM4E (0.49) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL16136333 0.74 KDM4E (0.44) KDM4ECYP3A4MAPTIDO1ALDH1A1
SCHEMBL16064993 0.74 KDM4E (0.47) KDM4ECYP3A4MAPTIDO1ADORA3
SCHEMBL2950095 0.73 GPR84 (0.48) KDM4ECYP3A4MAPTADORA3ADORA2A
SCHEMBL8784980 0.72 DRD4 (0.53) KDM4EMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025098545-A1 NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) 2025-05-15 WO disclosed
EP-4553080-A1 NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2025-05-14 EP disclosed
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1888529-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-02-20 EP disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed
WO-2006124692-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed
WO-2006085494-A1 FLAME-RETARDANT COMPOSITION FOR SOLDER RESIST AND USE THEREOF SHOWA DENKO K.K. (JP) 2006-08-17 WO disclosed
US-5606073-A INTERMEDIATES FOR ADENOSINE ANTAGONISTS EISAI CO., LTD. (JP) 1997-02-25 US disclosed
US-5541213-A ADENOSINE A1 RECEPTOR ANTAGONISTS, TREATMENT OF KIDNEY DISORDERS EISAI CO., LTD. (JP) 1996-07-30 US disclosed
EP-0630894-A1 Propenoic acid derivatives as adenosine A1 antagonists Eisai Co., Ltd. (JP) 1994-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010188-A1 Imidazopyridine Compounds SSB, MIF, IDO1 KDM4E 2671/4885CYP3A4 66/4885MAPT 3076/4885
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 KDM4E 2671/4885CYP3A4 66/4885MAPT 3076/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT KDM4E 2821/4885CYP3A4 79/4885MAPT 2195/4885
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 KDM4E 1032/4885CYP3A4 2706/4885MAPT 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.